Bioeq AG is a Swiss biopharmaceutical joint venture of Polpharma Biologics Group and Formycon AG based in Zug, Switzerland. We license, develop and commercialise our biosimilar ranibizumab. This is our successor of Lucentis®, a successful branded biopharmaceutical.
Bioeq AG out-licenses its product only to established international pharmaceutical companies in order to ensure local distribution in each territory.
Also, for Switzerland, Bioeq AG is holding the marketing authorisation for Ranivisio®, the medical product containing ranibizumab as the active substance.
Information on the safe use of Ranivisio® is presented here.
We are a young company, very dynamic, and supported by an international network of experts.
We are currently not hiring
Phone: +41 44 533 41 00